AVAPRO: Powerful Monotherapy in Mild-to-Moderate Hypertensive Patients

AVAPRO is a once-a-day oral angiotensin II receptor blocker (ARB) with demonstrated efficacy in treating hypertension. The efficacy of AVAPRO has been established by 7 major placebo-controlled trials in 1,915 patients with baseline diastolic blood pressure (DBP) of 95 to 110 mm Hg.
AVAPRO demonstrated powerful SBP and DBP reductions comparable to one of the most widely prescribed antihypertensive agents, amlodipine, at starting doses.¹⁶

4-week, multicenter, randomized, double-blind, comparative study.
Primary end point: mean DBP change from baseline to Week 4.
Mean age, 51 years; 63% male; 87% Caucasian.

Dizziness was the most commonly reported adverse event.

Download additional study information following the full Prescribing Information.

AVAPRO demonstrated once-daily superior DBP-reducing power vs losartan at maximum once-daily doses.*^18,19

Kassler-Taub et al¹⁸:

8-week, multicenter, randomized, double-blind, placebo-controlled comparative study.
Primary end point: mean DBP change from baseline to Week 8.

The most common adverse events were headache, musculoskeletal pain, dizziness, upper respiratory infection, and fatigue.

Download additional study information following the full Prescribing Information.

Superiority demonstrated in another well-controlled DBP reduction trial*¹⁹

Oparil et al¹⁹:

• AVAPRO 150-mg and AVAPRO 300-mg once daily (n=178): -10.2 mm Hg in DBP at Week 8
• Losartan 50-100 mg once daily (n=192): -7.9 mm Hg in DBP at Week 8
• AVAPRO demonstrated a statistically significant (P<.02) difference of 2.3 mm Hg — a 29% greater DBP reduction vs losartan

12-week, multicenter, randomized, double-blind, elective titration comparative study.
Primary end point: mean DBP change from baseline to Week 8.

The most common adverse events were headache and dizziness.

*	These studies were conducted on hypertensive patients only and were designed to demonstrate significant DBP lowering between 2 ARBs. A comparison between once-daily AVAPRO and twice-daily losartan was not conducted in these studies.